Placebo for Efimosfermin alfa. clinical trials

A Phase 3, Randomized, Double-Blind, Placebo-Controlled, 3-Arm Study to Investigate the Safety and Efficacy of Efimosfermin Alfa in Participants With Biopsy-Confirmed F2- or F3-Stage Metabolic Dysfunction-Associated Steatohepatitis (MASH) (ZENITH-1)

This study is testing a new medicine, Efimosfermin alfa, for people with a type of liver disease called MASH. We want to see if it can improve liver scarring and damage. One group will get the medicine, and others will get a dummy treatment.